November 2023
1. 
   Viral, cellular and immune aspects of non-suppressible HIV-1 viremia.
   Nat Med. 2023 Nov 23. doi: 10.1038/s41591-023-02688.
   

   >> Share

   
   
2. ZHANG L, Iannuzzi S, Chaturvedula A, Irungu E, et al
   Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women.
   Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02615.
   

   >> Share

   
   
3. WONG CKH, Lau KTK, Chung MSH, Au ICH, et al
   Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.
   Nat Med. 2023 Nov 1. doi: 10.1038/s41591-023-02674.
   

   >> Share

   
   October 2023
4. MOORE M, Stansfield S, Donnell DJ, Boily MC, et al
   Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
   Nat Med. 2023 Oct 5. doi: 10.1038/s41591-023-02564.
   

   >> Share

   
   October 2021
5. STEPHENSON KE, Julg B, Tan CS, Zash R, et al
   Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial.
   Nat Med. 2021 Oct 7. pii: 10.1038/s41591-021-01509.
   

   >> Share

   
   April 2020
6. STOWER H
   Lopinavir-ritonavir in severe COVID-19.
   Nat Med. 2020 Apr 9. pii: 10.1038/s41591-020-0849.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share